anti-hiv-agents

Documents about anti-hiv-agents

• Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling#980322ClinicalTrials.gov
• Rapid HIV Tests for Women Late in Pregnancy and During Labor#869268ClinicalTrials.gov
• Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy#836882ClinicalTrials.gov
• A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)#869163ClinicalTrials.gov
• A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible#839368ClinicalTrials.gov
• The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine#810511ClinicalTrials.gov
• Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs#982791ClinicalTrials.gov
• The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine#844485ClinicalTrials.gov
• Study of Pharmacokinetics in HIV-infected Women#893061ClinicalTrials.gov
• Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3#813434ClinicalTrials.gov
• Scaling-up highly active antiretroviral therapy (HAART) in Peru: Problems on the horizon [2]#277459Repositorio Universidad Peruana Cayetano Heredia
• A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients#865978ClinicalTrials.gov
• Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection#881573ClinicalTrials.gov
• A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection#868894ClinicalTrials.gov
• A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients#825782ClinicalTrials.gov
• A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir#837945ClinicalTrials.gov
• Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure#836627ClinicalTrials.gov
• Guidelines for HIV diagnosis and monitoring of antiretroviral therapy#627348WHO IRIS
• A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients#812872ClinicalTrials.gov
• Long-Term Data Collection From Participants in Adult AIDS Clinical Trials#893700ClinicalTrials.gov
• A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients#805829ClinicalTrials.gov
• Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers#865790ClinicalTrials.gov
• A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults#992730ClinicalTrials.gov
• The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors#883800ClinicalTrials.gov
• Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults#900047ClinicalTrials.gov
• An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen#843766ClinicalTrials.gov
• Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach#373060WHO IRIS
• Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients#846251ClinicalTrials.gov
• TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients#859109ClinicalTrials.gov
• The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients#861195ClinicalTrials.gov
• The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors#982777ClinicalTrials.gov
• Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies#836571ClinicalTrials.gov
• Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach#373059WHO IRIS
• Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns#863517ClinicalTrials.gov
• A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.#830998ClinicalTrials.gov
• Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach - 2010 version#376865WHO IRIS
• A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients#873814ClinicalTrials.gov
• Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment#876734ClinicalTrials.gov
• A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors#881227ClinicalTrials.gov
• Антиретровирусная терапия ВИЧ-инфекции у взрослых и подростков: Рекомендации с позиций Общественного здравоохранения. Пересмотренное издание 2010 г.#376868WHO IRIS
• A Study of the Effects of Advantage 24 on the Rectum#891386ClinicalTrials.gov
• Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex E: predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study#376871WHO IRIS
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.#866508ClinicalTrials.gov
• A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3#811169ClinicalTrials.gov
• Recommandations rapides : médicants antirétroviraux pour traiter la femme enceinte et prévenir l'infection à VIH chez l'enfant#621295WHO IRIS
• Traitement antirétroviral de l'infection à VIH chez l'adulte et l'adolescent: recommandations pour une approche de santé publique -- mise à jour 2010#376870WHO IRIS
• Lignes directrices unifiées sur l’utilisation des antirétroviraux pour le traitement et la prévention de l’infection à VIH : recommandations pour une approche de santé publique#373049WHO IRIS